ClinicalTrials.gg
Not yet recruitingNCT07454200Updated Mar 6, 2026

Feasibility, Acceptability, and Effectiveness of a Hatha Yoga-in Patients Hospitalized for Schizophrenia

An interventional study of Intervention Arm: Hatha Yoga in SCHIZOPHRENIA 1 (Disorder) and Hospitalized Adult Patients, sponsored by The Hashemite University. Not yet recruiting. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by The Hashemite University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Study summary

The current study aims to examine the feasibility, acceptability, and preliminary effectiveness of a Hatha yoga-based group intervention on reminiscence functions and mindfulness in a sample of patients hospitalized for schizophrenia.

Read the detailed description

This study employs a mixed-methods sequential explanatory design. Convenience sampling will be used to recruit 36 participants for a cross-culturally adapted Hatha yoga-based group intervention (16 one hour-long sessions over 8 weeks). Feasibility indicators will be monitored systematically. Acceptability will be assessed using semi-structured interviews. Preliminary effectiveness will be evaluated using a quasi-experimental one-group pre-post test design to test group-level (paired t-test) and individual-level (reliability change index) changes in mindfulness and reminiscence functions. Thematic analysis will be conducted to analyze qualitative data, with meta-inference used to integrate the qualitative and quantitative findings.

02

Conditions studied

  • SCHIZOPHRENIA 1 (Disorder)
  • Hospitalized Adult Patients

Browse trials for

03

In context

Schizophrenia

3,563 studies on the registry are indexed under Schizophrenia; 491 are open to participants now.

This study's planned enrollment of 36 is below the median of 71 across 2,944 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

The Hashemite University is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients are diagnosed with schizophrenia according to the or ICD-10 criteria
  • Patients are aged between 18 and 65 years old
  • Patients are clinically stabile, defined as being in the post-acute phase of care with no acute psychotic episode or psychiatric hospitalization within the 30 days preceding enrollment
  • Patients have adequate cognitive functioning, as evidenced by passing the (MMSE), with sufficient insight and capacity to respond meaningfully to study procedures
  • Patients have the ability to attend group-based sessions and provide
  • Patients have the willingness and physical ability to engage safely in light-to-moderate yoga practice.

Exclusion criteria

Exclusion Criteria:

  • Patients with severe cognitive impairment or intellectual disability that would disqualify meaningful participation
  • Patients with acute psychiatric symptoms or active suicidal ideation
  • Patients with physical limitations, such as a severe musculoskeletal condition, that would contraindicate safe participation in yoga practice.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Experimental

    Hatha Yoga-Based Group Intervention

    Behavioral: Intervention Arm: Hatha Yoga

Interventions

  • BehavioralIntervention Arm: Hatha Yoga

    Hatha Yoga balances the body's "sun" (ha) and "moon" (tha) energies to promote physical, mental, and emotional wellness. There will be eight two-hour Hatha yoga-based group therapy sessions over eight weeks. A professional yoga teacher and mental health nurse will lead these helpful sessions. Better memory and alertness are the major goals. To ensure participant safety and study validity, a multidisciplinary team assesses health, trauma triggers, and personal goals before the program begins. The lessons are held in a comfortable area with adjustable props and lighting. Trainers employ trauma-sensitive language and retain privacy on all participants, including "Hesitant" and "Overwhelmed." Each session includes grounding, pranayama, asana, and dhyana.

06

What researchers measure

Primary outcomes

  1. The Five-Facet Mindfulness Questionnaire-15 (FFMQ-15)

    The Five-Facet Mindfulness Questionnaire-15 is a 15-item self-report measure assessing five domains: observing, describing, acting with awareness, nonjudging, and nonreactivity. Each item is rated on a 5-point Likert scale from 1 to 5. Total scores range from 15 to 75. Higher scores indicate higher levels of dispositional mindfulness, reflecting a better outcome.

    Time frame: 12 weeks

  2. Feasibility Indicators: Recruitment Retention Attrition Adherence Data completeness Adverse events.

    1. Recruitment rate: Percentage of eligible participants enrolled during the 10-week recruitment period, calculated as the number who provide written consent divided by the total eligible participants approached, multiplied by 100. 2. Retention rate: Percentage of enrolled participants who complete the week 10 assessment, calculated as completers divided by total enrolled at baseline, multiplied by 100. 3. Attrition rate: Percentage of participants who withdraw before week 10, calculated as discontinuations divided by total enrolled, multiplied by 100. 4. Adherence: Attendance rate across scheduled sessions, calculated as sessions attended divided by total sessions, multiplied by 100. 5. Data completeness: Percentage of completed outcome assessment items at baseline and week 10, calculated as completed items divided by total expected items, multiplied by 100. 6. Adverse events: Number and proportion of participants experiencing adverse events during the intervention period.

    Time frame: 10 weeks

Secondary outcomes

  1. The 18-item Tripartite Adjusted Arabic Reminiscence Functions Scale (AARFS-tri)

    The 18-item Tripartite Adjusted Arabic Reminiscence Functions Scale assesses three core reminiscence functions: positive reminiscence, negative reminiscence, and social reminiscence. Each item is rated on a 6-point Likert scale from 1, never, to 6, very often. Total scores range from 18 to 108, with higher total scores indicating greater overall use of reminiscence functions. The scale includes three 6-item subscales. The Positive Reminiscence Subscale measures adaptive functions such as identity consolidation, meaning making, problem solving, and positive emotion regulation, with scores ranging from 6 to 36, where higher scores reflect more frequent use of adaptive reminiscence strategies. The Negative Reminiscence Subscale assesses maladaptive functions such as rumination, regret, bitterness revival, and mood worsening, with scores ranging from 6 to 36, where higher scores indicate more frequent maladaptive reminiscence patterns.

    Time frame: 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Nov 2026, 7 months later.

Of 753 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 7 months is below that.

Counting every sponsor, half of 766 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 6, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 1, 2027
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07454200
Lead sponsor
The Hashemite University
Responsible party
Abdallah Abu Khait (Dr., The Hashemite University) — Principal investigator
First posted
Mar 6, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Mar 6, 2026

Study contacts

Abdallah F Abu Khait, Ph.D, MSN
Contact
abdallah.abukhait@hu.edu.jo
+962792269831
Austin Menger, PhD
Contact
austin@mengeranalytics.com
516-220-7313
Abdallah Abu Khait, Ph.D.,MSN
principal investigator · The Hashemite University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion